SIRT2 and B-cell non-Hodgkin lymphoma: While all SIRT2 inhibitors were found to be toxic to B-cell lymphoma cell lines (Table 5), interestingly, primary carboxamide side chain containing inhibitors (e.g., 24, 22), which showed lower potencies in in vitro enzyme assays, displayed higher cytotoxicity as compared to other more potent inhibitors with polar side chains.